A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
Year: 2010
Type: article
Study design: Clinical Trial
Source: Investigational New Drugs
Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Center, Tisch Cancer Institute, Prostate Cancer Clinical Trials Consortium, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, CASI Pharmaceuticals (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W2079605491